Increased femoral head size reduces the rate of dislocation after total hip arthroplasty (THA). With the introduction of highly crosslinked polyethylene (HXLPE) liners in THA there has been a trend towards using larger size femoral heads in relatively smaller cup sizes, theoretically increasing the risk of liner fracture, wear, or aseptic loosening. Short to medium follow-up studies have not demonstrated a negative effect of using thinner HXLPE liners. However, there is concern that these thinner liners may prematurely fail in the long-term, especially in those with thinner liners. The aim of this study was to evaluate the long-term survival and revision rates of HXLPE liners in primary THA, as well as the effect of liner thickness on these outcomes. We hypothesized that there would be no significant differences between the different liner thicknesses. We performed a retrospective database analysis from a single center of all primary total hip replacements using HXLPE liners from 2010 and earlier, including all femoral head sizes. All procedures were performed by fellowship trained arthroplasty surgeons. Patient characteristics, implant details including liner thickness, death, and revisions (all causes) were recorded. Patients were grouped for analysis for each millimeter of PE thickness (e.g. 4.0-4.9mm, 5.0-5.9mm). Kaplan-Meier survival estimates were estimated with all-cause and aseptic revisions as the endpoints. A total of 2354 patients (2584 hips) were included (mean age 64.3 years, min-max 19-96). Mean BMI was 29.0 and 47.6% was female. Mean follow-up was 13.2 years (range 11.0-18.8). Liner thickness varied from 4.9 to 12.7 mm. Seven patients had a liner thickness <5.0mm and 859 had a liner thickness of <6.0mm. Head sizes were 28mm (n=85, 3.3%), 32mm (n=1214, 47.0%), 36mm (n=1176, 45.5%), and 40mm (n=109, 4.2%), and 98.4% were metal heads. There were 101 revisions, and in 78 of these cases the liner was revised. Reason for revision was instability/dislocation (n=34), pseudotumor/aseptic lymphocyte-dominant vasculitis associated lesion (n=18), fracture (n=17), early loosening (n=11), infection (n=7), aseptic loosening (n=4), and other (n=10). When grouped by liner thickness, there were no significant differences between the groups when looking at all-cause revision (p=0.112) or aseptic revision (p=0.116). In our cohort, there were no significant differences in all-cause or aseptic revisions between any of the liner thickness groups at long-term follow-up. Our results indicate that using thinner HXPE liners to maximize femoral head size in THA does not lead to increased complications or liner failures at medium to long term follow-up. As such, orthopedic surgeons can consider the use of larger heads at the cost of liner thickness a safe practice to reduce the risk of dislocation after THA when using HXLPE liners

Metal Bearings in Hip Arthroplasty – What Have We Learned?. Large metal on metal bearings have come back to hip arthroplasty the past five to ten years with great promise to minimize wear debris, eliminate osteolysis, reduce dislocations and improve range of motion. While some of these claims have proven to be true, new problems have surfaced that threaten the success of these devices. Metalosis, “pseudotumours” and ALVAL (aseptic lymphocytic vasculitis associated lesions) are appearing. These lesions produce pain that is difficult to confirm on routine exam and xray but eventually lead to early revision surgery. This paper will examine the advantages and complications of this hard bearing surface with a special look at complications, their prevention and management

The metal-on-metal total hip resurfacing arthroplasty is a good solution for the younger patient with osteoarthritis of the hip. It is effective in pain resolution and provides a good function. Our study of 300 BHR arthroplasties with a follow-up of 2 to 7 year shows good results in a young and active population. With an overall survival of 96.7% we obtained similar results to those of the design centre. The overall postoperative HHS score of 95.78 +/− 12.63 is in line with other studies. We noticed a similar increase in HHS in female patients and male patients. Even in the HOOS scores there was no significant difference between both groups. This is an important finding for the surgeon as well as the patients. Looking at the VAS scores for satisfaction or reoperation we could state that the high expectations of this population have been fulfilled. With have an acceptable revision rate of 2.42% the patients undergoing a revision were of a simular mean age than those in the overall group. Five of them are female, two are male. Since there were twice as many female as male patients there is little difference in revision percentage between both groups. There was 1 patient with a bilateral revision because of ALVAL (aseptic lymphocytic vasculitis associated lesion). Although femoral neck fractures are a known complication, there where none in our series. Patients are able to lead an active life and perform sports. The postoperative benefits are equal in men and women. The satisfaction rate confirms that we are able to meet the expectations in this high demand group

Aims

Diabetes mellitus is the most common co-morbidity associated with necrotising fasciitis. This study aims to compare the clinical presentation, investigations, Laboratory Risk Indicator for Necrotising Fasciitis (LRINEC) score, microbiology and outcome of management of this condition in diabetic and non-diabetic patients.

Bone-marrow oedema can occur both in isolation and in association with necrosis of bone, but it has not been shown whether each respond to the same methods of treatment.

We treated 16 patients with isolated oedema and 17, in which it was associated with necrosis of the proximal femur, with the prostacyclin derivative iloprost, which has been shown to be effective in the idiopathic form. The Harris hip score, the range of movement, the extent of the oedema as measured by MRI, pain on a visual analogue scale and patient satisfaction were recorded before and subsequent to treatment.

In both groups, we were able to show a significant improvement (p < 0.001) in these observations during the period of follow-up indicating that iloprost will produce clinical improvement in both circumstances.